JP2007515387A - 2−オキソ−1−ピロリジン誘導体の製造方法 - Google Patents
2−オキソ−1−ピロリジン誘導体の製造方法 Download PDFInfo
- Publication number
- JP2007515387A JP2007515387A JP2006527306A JP2006527306A JP2007515387A JP 2007515387 A JP2007515387 A JP 2007515387A JP 2006527306 A JP2006527306 A JP 2006527306A JP 2006527306 A JP2006527306 A JP 2006527306A JP 2007515387 A JP2007515387 A JP 2007515387A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- alkyl
- oxo
- compound
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 40
- 150000001875 compounds Chemical class 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- 239000003054 catalyst Substances 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000002252 acyl group Chemical group 0.000 claims description 9
- 125000004423 acyloxy group Chemical group 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 9
- 125000004414 alkyl thio group Chemical group 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 9
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 9
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 9
- 125000005110 aryl thio group Chemical group 0.000 claims description 9
- 125000004104 aryloxy group Chemical group 0.000 claims description 9
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 9
- -1 R b Chemical group 0.000 claims description 8
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 8
- SIVBVNKKRKAXNV-UHFFFAOYSA-N cyanatosulfonylformic acid Chemical compound OC(=O)S(=O)(=O)OC#N SIVBVNKKRKAXNV-UHFFFAOYSA-N 0.000 claims description 8
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 8
- 150000002240 furans Chemical class 0.000 claims description 7
- MSYKRHVOOPPJKU-BDAKNGLRSA-N brivaracetam Chemical compound CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-BDAKNGLRSA-N 0.000 claims description 6
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 229910052763 palladium Inorganic materials 0.000 claims description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 2
- 150000004715 keto acids Chemical class 0.000 claims description 2
- 238000006386 neutralization reaction Methods 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- HNNJFUDLLWOVKZ-VKHMYHEASA-N (2s)-2-aminobutanamide Chemical compound CC[C@H](N)C(N)=O HNNJFUDLLWOVKZ-VKHMYHEASA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- HPHUVLMMVZITSG-LURJTMIESA-N levetiracetam Chemical compound CC[C@@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-LURJTMIESA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- KQMCGGGTJKNIMC-UHFFFAOYSA-N 2-hydroxy-3-propyl-2h-furan-5-one Chemical compound CCCC1=CC(=O)OC1O KQMCGGGTJKNIMC-UHFFFAOYSA-N 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000010533 azeotropic distillation Methods 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 3
- 229940011051 isopropyl acetate Drugs 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
- 229960004002 levetiracetam Drugs 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000004040 pyrrolidinones Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- FIVVRGAOWICBAV-DFWYDOINSA-N (2s)-2-aminobutanamide;2,3-dihydroxybutanedioic acid Chemical compound CC[C@H](N)C(N)=O.OC(=O)C(O)C(O)C(O)=O FIVVRGAOWICBAV-DFWYDOINSA-N 0.000 description 1
- WXFWXFIWDGJRSC-UHFFFAOYSA-N 2,5-dimethoxy-2,5-dihydrofuran Chemical compound COC1OC(OC)C=C1 WXFWXFIWDGJRSC-UHFFFAOYSA-N 0.000 description 1
- IZTLHMKJHPBCBY-UHFFFAOYSA-N 3-hydroxy-4-propyl-3h-furan-2-one Chemical compound CCCC1=COC(=O)C1O IZTLHMKJHPBCBY-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 0 CC(*)N(CC(C)C1*)C1=O Chemical compound CC(*)N(CC(C)C1*)C1=O 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- NGPGDYLVALNKEG-UHFFFAOYSA-N azanium;azane;2,3,4-trihydroxy-4-oxobutanoate Chemical compound [NH4+].[NH4+].[O-]C(=O)C(O)C(O)C([O-])=O NGPGDYLVALNKEG-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000002050 international nonproprietary name Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VMVVZQZMGXGYJC-MLWJPKLSSA-N methyl 1-[(2s)-1-amino-1-oxobutan-2-yl]-5-oxopyrrolidine-3-carboxylate Chemical compound CC[C@@H](C(N)=O)N1CC(C(=O)OC)CC1=O VMVVZQZMGXGYJC-MLWJPKLSSA-N 0.000 description 1
- ANLXZUOWYXCFKW-UHFFFAOYSA-N methyl 2-hydroxy-5-oxo-2h-furan-3-carboxylate Chemical compound COC(=O)C1=CC(=O)OC1O ANLXZUOWYXCFKW-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 238000004262 preparative liquid chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
Abstract
Description
R1は、Ra又はRbであり;
R3及びR4は、同じか又は異なり、夫々独立に、水素、ヒドロキシ、チオール、ハロゲン、シアノ、カルボキシ、スルホン酸、Ra、Rb、アルキルスルホニル、アリールスルホニル、アルキルスルフィニル、アリールスルフィニル、アルキルチオ、アリールチオ、アルコキシ、アリールオキシ、スルホンアミド、アシル、エステル、アミド、アシルオキシ、エステルオキシ、又はアミドオキシであり;
Xは、−CONR5R6、−COOR7、又は−CNであり;
R5、R6、R7は、同じか又は異なり、夫々独立に、水素、Ra、又はRbであり;
Raは、C1−20アルキル、又は一つ以上のヒドロキシ、チオール、ハロゲン、シアノ、カルボキシ、スルホン酸、Rb、アルキルスルホニル、アリールスルホニル、アルキルスルフィニル、アリールスルフィニル、アルキルチオ、アリールチオ、アルコキシ、アリールオキシ、スルホンアミド、アシル、エステル、アミド、アシルオキシ、エステルオキシ、及び(又は)アミドオキシにより置換されたC1−20アルキルであり;
Rbは、アリール、ヘテロアリール、ヘテロシクロアルキル、又はそれらの、一つ以上のRa、ヒドロキシ、チオール、ハロゲン、シアノ、カルボキシ、スルホン酸、アリール、アルキルスルホニル、アリールスルホニル、アルキルスルフィニル、アリールスルフィニル、アルキルチオ、アリールチオ、アルコキシ、アリールオキシ、スルホンアミド、ヘテロシクロアルキル、ヘテロアリール、アシル、エステル、アミド、アシルオキシ、エステルオキシ、及び(又は)アミドオキシにより置換されたものである。)
の2−オキソ−1−ピロリジン誘導体及びその塩を製造する方法であって、
式(II)又は(III):
のフラン誘導体と、式(IV):
Raは、C1−20アルキル、又は一つ以上のヒドロキシ、チオール、ハロゲン、シアノ、カルボキシ、スルホン酸、アリール、アルキルスルホニル、アリールスルホニル、アルキルスルフィニル、アリールスルフィニル、アルキルチオ、アリールチオ、アルコキシ、アリールオキシ、スルホンアミド、ヘテロシクロアルキル、ヘテロアリール、アシル、エステル、アミド、アシルオキシ、エステルオキシ、及び(又は)アミドオキシにより置換されたC1−20アルキルであり;そして
Rbは、好ましくはアリール、ヘテロアリール、ヘテロシクロアルキル、又はそれらの、一つ以上のアルキル、ヒドロキシ、チオール、ハロゲン、シアノ、カルボキシ、スルホン酸、アリール、アルキルスルホニル、アリールスルホニル、アルキルスルフィニル、アリールスルフィニル、アルキルチオ、アリールチオ、アルコキシ、アリールオキシ、スルホンアミド、ヘテロシクロアルキル、ヘテロアリール、アシル、エステル、アミド、アシルオキシ、エステルオキシ、及び(又は)アミドオキシにより置換されたものである。
Xは、好ましくは−CONR5R6、一層好ましくは−CONH2であり、
R1は、好ましくはC1−6アルキルであり、一層好ましくは、メチル、チル、n−プロピル、イソプロピル、n−ブチル、又はイソブチル、最も好ましくはメチル、エチル、又はn−プロピル、特にエチルである。
1.1 (2S)−2−アミノブチルアミド遊離塩基の合成
1.3で得られた二種類のジアステレオ異性体のクロマトグラフ分離を、〔キラルパク(CHIRALPAK)AD20μm〕キラル固定相及び溶離剤としてn−ヘプタンとエタノールとの45/55(体積/体積)混合物を用いて、25±2℃の温度で遂行する。
Claims (18)
- 一般式(I):
(式中、
R1は、Ra又はRbであり;
R3及びR4は、同じか又は異なり、夫々独立に、水素、ヒドロキシ、チオール、ハロゲン、シアノ、カルボキシ、スルホン酸、Ra、Rb、アルキルスルホニル、アリールスルホニル、アルキルスルフィニル、アリールスルフィニル、アルキルチオ、アリールチオ、アルコキシ、アリールオキシ、スルホンアミド、アシル、エステル、アミド、アシルオキシ、エステルオキシ、又はアミドオキシであり;
Xは、−CONR5R6、−COOR7、又は−CNであり;
R5、R6、R7は、同じか又は異なり、夫々独立に、水素、Ra、又はRbであり;
Raは、C1−20アルキル、又は一つ以上のヒドロキシ、チオール、ハロゲン、シアノ、カルボキシ、スルホン酸、Rb、アルキルスルホニル、アリールスルホニル、アルキルスルフィニル、アリールスルフィニル、アルキルチオ、アリールチオ、アルコキシ、アリールオキシ、スルホンアミド、アシル、エステル、アミド、アシルオキシ、エステルオキシ、及び(又は)アミドオキシにより置換されたC1−20アルキルであり;
Rbは、アリール、ヘテロアリール、ヘテロシクロアルキル、又はそれらの、一つ以上のRa、ヒドロキシ、チオール、ハロゲン、シアノ、カルボキシ、スルホン酸、アリール、アルキルスルホニル、アリールスルホニル、アルキルスルフィニル、アリールスルフィニル、アルキルチオ、アリールチオ、アルコキシ、アリールオキシ、スルホンアミド、ヘテロシクロアルキル、ヘテロアリール、アシル、エステル、アミド、アシルオキシ、エステルオキシ、及び(又は)アミドオキシにより置換されたものである。)
の2−オキソ−1−ピロリジン誘導体及びその塩を製造する方法であって、
式(II)又は(III):
(式中、R2及びR2′は、同じか又は異なり、夫々C1−10アルキル、又はそれらの、アリールにより置換されたものである。)
のフラン誘導体と、式(IV):
の化合物及びH2と、触媒を存在させて反応させることを含む製造方法。 - 式(II)のフラン誘導体を用いる、請求項1に記載の方法。
- R3が水素である、請求項1又は2に記載の方法。
- R4が、Ra又は水素である、請求項2〜3のいずれか1項に記載の方法。
- R4が、C1−6アルキル、又は一つ以上のハロゲンによって置換されたC1−6アルキルである、請求項4に記載の方法。
- R4がn−プロピルである、請求項5に記載の方法。
- Xが−CONR5R6である、請求項1〜6のいずれか1項に記載の方法。
- Xが−CONH2である、請求項7に記載の方法。
- R1が、C1−6アルキルである、請求項1〜8のいずれか1項に記載の方法。
- R1がエチルである、請求項9に記載の方法。
- 式(IV)の化合物を、対応する塩酸塩の中和により得る、請求項1〜11のいずれか1項に記載の方法。
- 触媒が、Pd、Pt、又はNi系触媒である、請求項1〜12のいずれか1項に記載の方法。
- 触媒が、Pd系触媒である、請求項13に記載の方法。
- 式(I)の化合物が、(S)−型又は(R)−型になっている、請求項1〜14のいずれか1項に記載の方法。
- 式(I)の化合物が、(S)−型になっている、請求項15に記載の方法。
- R3及び(又は)R4が水素とは異なる場合、得られたジアステレオ異性体を更に分離する、請求項1〜16のいずれか1項に記載の方法。
- (2S)−2−[(4R)−2−オキソ−4−n−プロピル−1−ピロリジニル]ブタンアミドを製造するために適用される、請求項1〜17のいずれか1項に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03021534 | 2003-09-24 | ||
PCT/EP2004/010212 WO2005028435A1 (en) | 2003-09-24 | 2004-09-13 | Process for preparing 2-oxo-1-pyrrolidine derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007515387A true JP2007515387A (ja) | 2007-06-14 |
JP4658937B2 JP4658937B2 (ja) | 2011-03-23 |
Family
ID=34354424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006527306A Active JP4658937B2 (ja) | 2003-09-24 | 2004-09-13 | 2−オキソ−1−ピロリジン誘導体の製造方法 |
Country Status (15)
Country | Link |
---|---|
US (1) | US7629474B2 (ja) |
EP (1) | EP1667967B1 (ja) |
JP (1) | JP4658937B2 (ja) |
KR (1) | KR101124098B1 (ja) |
CN (1) | CN1882535B (ja) |
BR (1) | BRPI0414436A (ja) |
CA (1) | CA2538938C (ja) |
DK (1) | DK1667967T3 (ja) |
EA (1) | EA010306B1 (ja) |
ES (1) | ES2390455T3 (ja) |
HK (1) | HK1094702A1 (ja) |
IL (1) | IL174029A (ja) |
PL (1) | PL1667967T3 (ja) |
WO (1) | WO2005028435A1 (ja) |
ZA (1) | ZA200601970B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021527703A (ja) * | 2018-06-20 | 2021-10-14 | 上海朴▲イ▼化学科技有限公司 | ブリバラセタム中間体、その製造方法及びブリバラセタムの製造方法 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006103696A2 (en) * | 2005-04-01 | 2006-10-05 | Rubamin Laboratories Limited | Process for preparing levetiracetam and racemization of (r)- and (s)-2-amino butynamide and the corresponding acid derivatives |
EA016518B1 (ru) * | 2005-09-15 | 2012-05-30 | Юсб Фарма, С.А. | 4-замещенные пирролидин-2-оны и их применение |
EP1993998B1 (en) * | 2005-12-07 | 2013-08-21 | UCB Pharma, S.A. | 3-carboxy- 2-oxo-1 -pyrrolidine derivatives and their uses |
WO2016075082A1 (en) | 2014-11-10 | 2016-05-19 | Sandoz Ag | Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam |
JP6872500B2 (ja) | 2015-05-25 | 2021-05-19 | エステベ・キミカ・ソシエダッド・アノニマEsteve Quimica, S.A. | ブリバラセタムを製造する方法 |
WO2017076737A1 (en) | 2015-11-03 | 2017-05-11 | Ucb Biopharma Sprl | Continuous process for preparing brivaracetam |
PL3371150T3 (pl) | 2015-11-03 | 2022-01-17 | UCB Biopharma SRL | Sposób wytwarzania briwaracetamu |
CN105646319B (zh) * | 2015-12-30 | 2018-05-18 | 佛山市隆信医药科技有限公司 | 一种布瓦西坦的制备方法 |
CN107513031B (zh) * | 2016-06-16 | 2022-08-02 | 上海医药集团股份有限公司 | 一种2-氧代-1-吡咯烷手性衍生物的制备方法 |
CN108218757A (zh) * | 2016-12-14 | 2018-06-29 | 上海医药集团股份有限公司 | 对2-(4-丙基吡咯烷-2-酮)-丁酰胺非对映异构体的拆分方法 |
CN106748950B (zh) * | 2017-01-13 | 2019-09-03 | 成都美域高制药有限公司 | 一种布瓦西坦及其中间体的制备方法 |
CN108658831B (zh) * | 2017-03-30 | 2021-11-05 | 江苏豪森药业集团有限公司 | 2-氧代-1-吡咯烷衍生物或其盐的制备方法 |
CN107793342A (zh) * | 2017-10-19 | 2018-03-13 | 丽珠集团新北江制药股份有限公司 | 一种布瓦西坦的制备方法 |
CN108548873A (zh) * | 2018-03-20 | 2018-09-18 | 丽珠集团新北江制药股份有限公司 | 一种布瓦西坦中间体异构体的检测方法 |
CN108929289B (zh) * | 2018-06-19 | 2022-01-04 | 上海博氏医药科技有限公司 | 一种用于制备布瓦西坦的中间体化合物及其制备方法和用途 |
CN111333563B (zh) | 2018-12-19 | 2023-11-07 | 上海科胜药物研发有限公司 | 一种布瓦西坦中间体的制备方法 |
CN111892526A (zh) * | 2019-05-06 | 2020-11-06 | 北京万全德众医药生物技术有限公司 | 一种布瓦西坦的新制备方法 |
EP4144724A4 (en) | 2020-04-30 | 2023-03-15 | Shanghai Syncores Technologies Inc. Ltd. | BRIVARACETAM AND PROCESS FOR MAKING AN INTERMEDIATE THEREOF |
WO2023100110A1 (en) | 2021-12-02 | 2023-06-08 | Macfarlan Smith Limited | Process for preparing brivaracetam |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003523996A (ja) * | 2000-02-23 | 2003-08-12 | ユセベ,ソシエテ アノニム | 2−オキソ−1−ピロリジン誘導体、それらの製造方法及びそれらの使用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8412357D0 (en) * | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
GB8827389D0 (en) * | 1988-11-23 | 1988-12-29 | Ucb Sa | Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide |
US20040092575A1 (en) * | 2001-03-22 | 2004-05-13 | Jacques Peuvot | Use of certain substituted pyrrolidones such as piracetam in the treatment of viral and other diseases |
EP1395560A1 (en) | 2001-05-23 | 2004-03-10 | Ucb, S.A. | 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders |
ATE410412T1 (de) * | 2001-08-10 | 2008-10-15 | Ucb Pharma Sa | Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen |
-
2004
- 2004-09-13 EP EP04765134A patent/EP1667967B1/en active Active
- 2004-09-13 US US10/572,579 patent/US7629474B2/en active Active
- 2004-09-13 KR KR1020067005793A patent/KR101124098B1/ko active IP Right Grant
- 2004-09-13 DK DK04765134.4T patent/DK1667967T3/da active
- 2004-09-13 ZA ZA200601970A patent/ZA200601970B/en unknown
- 2004-09-13 CA CA2538938A patent/CA2538938C/en active Active
- 2004-09-13 EA EA200600485A patent/EA010306B1/ru not_active IP Right Cessation
- 2004-09-13 JP JP2006527306A patent/JP4658937B2/ja active Active
- 2004-09-13 ES ES04765134T patent/ES2390455T3/es active Active
- 2004-09-13 PL PL04765134T patent/PL1667967T3/pl unknown
- 2004-09-13 BR BRPI0414436-8A patent/BRPI0414436A/pt not_active Application Discontinuation
- 2004-09-13 CN CN200480033998XA patent/CN1882535B/zh active Active
- 2004-09-13 WO PCT/EP2004/010212 patent/WO2005028435A1/en active Application Filing
-
2006
- 2006-03-01 IL IL174029A patent/IL174029A/en active IP Right Grant
-
2007
- 2007-02-16 HK HK07101917.1A patent/HK1094702A1/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003523996A (ja) * | 2000-02-23 | 2003-08-12 | ユセベ,ソシエテ アノニム | 2−オキソ−1−ピロリジン誘導体、それらの製造方法及びそれらの使用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021527703A (ja) * | 2018-06-20 | 2021-10-14 | 上海朴▲イ▼化学科技有限公司 | ブリバラセタム中間体、その製造方法及びブリバラセタムの製造方法 |
JP7097467B2 (ja) | 2018-06-20 | 2022-07-07 | 上海朴▲イ▼化学科技有限公司 | ブリバラセタム中間体、その製造方法及びブリバラセタムの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1667967A1 (en) | 2006-06-14 |
EP1667967B1 (en) | 2012-08-01 |
CA2538938C (en) | 2011-08-09 |
BRPI0414436A (pt) | 2006-11-14 |
AU2004274157A1 (en) | 2005-03-31 |
EA010306B1 (ru) | 2008-08-29 |
ZA200601970B (en) | 2007-05-30 |
KR20060121889A (ko) | 2006-11-29 |
EA200600485A1 (ru) | 2007-02-27 |
KR101124098B1 (ko) | 2012-03-21 |
US7629474B2 (en) | 2009-12-08 |
CN1882535B (zh) | 2011-05-11 |
US20070100150A1 (en) | 2007-05-03 |
ES2390455T3 (es) | 2012-11-13 |
PL1667967T3 (pl) | 2012-11-30 |
HK1094702A1 (ja) | 2007-04-04 |
WO2005028435A1 (en) | 2005-03-31 |
CN1882535A (zh) | 2006-12-20 |
IL174029A (en) | 2012-06-28 |
IL174029A0 (en) | 2006-08-01 |
CA2538938A1 (en) | 2005-03-31 |
JP4658937B2 (ja) | 2011-03-23 |
DK1667967T3 (da) | 2012-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4658937B2 (ja) | 2−オキソ−1−ピロリジン誘導体の製造方法 | |
EP2029541B1 (en) | Process for preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carboxylic acids | |
JP4866352B2 (ja) | 2−オキソ−1−ピロリジン誘導体の製造方法 | |
Coke et al. | Synthesis of optically active. delta.-n-hexadecalactone, the proposed pheromone from Vespa orientalis | |
CN101511786A (zh) | 制备左乙拉西坦的方法 | |
JP3035356B2 (ja) | ピロリジニルヒドロキサム酸化合物及びその製造方法 | |
Tayama et al. | Resolution of nitrogen-centered chiral tetraalkylammonium salts: application to [1, 2] Stevens rearrangements with N-to-C chirality transmission | |
JP2001270865A (ja) | エタンスルホニルピペリジン誘導体の製造方法 | |
AU2004274157B2 (en) | Process for preparing 2-oxo-1-pyrrolidine derivatives | |
JP6483145B2 (ja) | アミドアセタール、ケテン−n,o−アセタール、又はエステルイミドからアミンを製造するための接触水素化 | |
JPH08502738A (ja) | アミド誘導体 | |
MXPA06003024A (en) | Process for preparing 2-oxo-1-pyrrolidine derivatives | |
EA019890B1 (ru) | 4r,5s-энантиомер 2-(5-метил-2-оксо-4-фенилпирролидин-1-ил)ацетамида с ноотропной активностью | |
JP2006312626A (ja) | 光学活性アミノアルコールの製造法 | |
JP2008531620A (ja) | ピログルタミン酸塩並びにデキストロセチリジン及びレボセチリジンの合成のための中間体の光学分割におけるその使用 | |
US7015320B2 (en) | Process for the manufacture of optically active 3-substituted lactams by asymmetric hydrogenation of 3-alkylidenelactams | |
WO2007069633A1 (ja) | インドリン誘導体 | |
KR20190077092A (ko) | 키랄 피롤리딘-2-일-메탄올 유도체의 제조 방법 | |
JP2005126380A (ja) | 光学活性な1,2−ビス(3,5−ジメチルフェニル)−1,2−エタンジアミンの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070712 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080205 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100820 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101118 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101214 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101224 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140107 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4658937 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |